Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Shanthi Marur, MD
CONTACT
Yifan Zhai, MD
CONTACT
Lead
Ascentage Pharma Group Inc.
Approximately 440 patients will be enrolled, the patients who meet the eligibility criteria will be randomized in a 1:1 ratio to investigational arm (lisaftoclax in combination with a BTK inhibitor) or the control arm (BTK inhibitor alone). These patients with CLL/SLL have been on BTKi monotherapy and meet all other protocol required eligibility criteria.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
